23 Recruiting Studies Using Cladribine
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Cladribine
Cladribine Venetoclax in Monocytic AML
📍 Universtiy of Colorado Hospital — Aurora, Colorado
Acute Myeloid Leukemia
View Study & Checklist ➔Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
📍 M D Anderson Cancer Center — Houston, Texas
Acute Myeloid Leukemia
View Study & Checklist ➔Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
Hairy Cell Leukemia
View Study & Checklist ➔Cladribine Tablets After Treatment With Natalizumab (CLADRINA)
📍 College Park Family Care Center Physicians Group — Overland Park, Kansas
Multiple Sclerosis
View Study & Checklist ➔Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
📍 University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
Acute Monocytic Leukemia
View Study & Checklist ➔Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
📍 Arizona Neuroscience Research, LLC — Phoenix, Arizona
Generalized Myasthenia Gravis
View Study & Checklist ➔Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
Acute Biphenotypic Leukemia
View Study & Checklist ➔Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations
📍 MD Anderson Cancer Center — Houston, Texas
Targeted Therapy
View Study & Checklist ➔Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
📍 M D Anderson Cancer Center — Houston, Texas
Acute Myeloid Leukemia
View Study & Checklist ➔A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)
📍 Dana Farber Cancer Institute — Boston, Massachusetts
Hairy Cell Leukemia
View Study & Checklist ➔BCL2i CLAG-M in R/R Acute Myeloid Leukemia
📍 Moffitt Cancer Center — Tampa, Florida
Relapsed or Refractory Acute Myeloid Leukemia (AML)
View Study & Checklist ➔A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
📍 M D Anderson Cancer Center — Houston, Texas
Myelodysplastic Syndromes
View Study & Checklist ➔Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia
📍 NCI - Center for Cancer Research — Bethesda, Maryland
Hairy Cell Leukemia
View Study & Checklist ➔CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
📍 University of Maryland Greenebaumn Comprehensive Cancer Center — Baltimore, Maryland
Acute Myeloid Leukemia, Adult
View Study & Checklist ➔Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia
📍 The University of Texas M. D. Anderson Cancer Center — Houston, Texas
T-cell Prolymphocytic Leukemia
View Study & Checklist ➔Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
Hairy Cell Leukemia
View Study & Checklist ➔Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
📍 M D Anderson Cancer Center — Houston, Texas
Acute Myeloid Leukemia
View Study & Checklist ➔Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
Acute Biphenotypic Leukemia
View Study & Checklist ➔Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
📍 University of Texas MD Anderson Cancer Center — Houston, Texas
Leukemia
View Study & Checklist ➔Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
📍 M D Anderson Cancer Center — Houston, Texas
Acute Myeloid Leukemia
View Study & Checklist ➔CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
Recurrent Acute Myeloid Leukemia
View Study & Checklist ➔Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML
📍 Stanford University — Palo Alto, California
Refractory Acute Myeloid Leukemia
View Study & Checklist ➔Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
Acute Myeloid Leukemia
View Study & Checklist ➔